NO20033950L - Farmasöytisk n¶ringspreparat omfattende polyfenoler og anvendelse i behandling av kreft - Google Patents

Farmasöytisk n¶ringspreparat omfattende polyfenoler og anvendelse i behandling av kreft

Info

Publication number
NO20033950L
NO20033950L NO20033950A NO20033950A NO20033950L NO 20033950 L NO20033950 L NO 20033950L NO 20033950 A NO20033950 A NO 20033950A NO 20033950 A NO20033950 A NO 20033950A NO 20033950 L NO20033950 L NO 20033950L
Authority
NO
Norway
Prior art keywords
cancer
polyphenols
treatment
nutritional composition
treating cancer
Prior art date
Application number
NO20033950A
Other languages
English (en)
Norwegian (no)
Other versions
NO20033950D0 (no
Inventor
Matthias Rath
Alexandra Niedzwiecki
Shrirang Netke
Original Assignee
Matthias Rath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23366808&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20033950(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Matthias Rath filed Critical Matthias Rath
Publication of NO20033950D0 publication Critical patent/NO20033950D0/no
Publication of NO20033950L publication Critical patent/NO20033950L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Botany (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
NO20033950A 2002-01-11 2003-09-05 Farmasöytisk n¶ringspreparat omfattende polyfenoler og anvendelse i behandling av kreft NO20033950L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34814302P 2002-01-11 2002-01-11
PCT/EP2003/000236 WO2003057201A2 (fr) 2002-01-11 2003-01-13 Formulation pharmaceutique d'elements nutritifs contenant des polyphenols et son utilisation dans le traitement du cancer

Publications (2)

Publication Number Publication Date
NO20033950D0 NO20033950D0 (no) 2003-09-05
NO20033950L true NO20033950L (no) 2003-11-10

Family

ID=23366808

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033950A NO20033950L (no) 2002-01-11 2003-09-05 Farmasöytisk n¶ringspreparat omfattende polyfenoler og anvendelse i behandling av kreft

Country Status (26)

Country Link
US (2) US7041699B2 (fr)
EP (1) EP1465614B1 (fr)
JP (1) JP2005519055A (fr)
KR (1) KR20040073559A (fr)
CN (1) CN100377706C (fr)
AT (1) ATE382343T1 (fr)
AU (1) AU2003235762B2 (fr)
BR (1) BR0302672A (fr)
CA (1) CA2471932A1 (fr)
DE (1) DE60318387T2 (fr)
EE (1) EE200400032A (fr)
ES (1) ES2298519T3 (fr)
HR (1) HRP20040704A2 (fr)
HU (1) HUP0500498A3 (fr)
IL (1) IL162646A0 (fr)
LT (1) LT5240B (fr)
LV (1) LV13248B (fr)
MX (1) MXPA04006717A (fr)
NO (1) NO20033950L (fr)
NZ (1) NZ533737A (fr)
PL (1) PL215159B1 (fr)
RU (1) RU2301666C2 (fr)
UA (1) UA80692C2 (fr)
WO (1) WO2003057201A2 (fr)
YU (1) YU75003A (fr)
ZA (1) ZA200405075B (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034310B2 (en) * 2002-02-21 2015-05-19 Stephen B. Cantrell Interferon-statin combination cancer therapy
US7115283B2 (en) * 2003-05-06 2006-10-03 Access Business Group International Llc Preparations for sustained release of nutraceuticals and methods of controllably releasing nutraceuticals
US20040253319A1 (en) * 2003-06-11 2004-12-16 Shrirang Netke Pharmaceutical compositions and method for alleviating side-effects of estrogen replacement therapy
KR20060069850A (ko) 2003-09-05 2006-06-22 마티아스 라트 비타민 ｃ, 마그네슘, 녹차 추출물을 포함하는 심장혈관계질환을 억제하기 위한 약제 조성물
US8377904B2 (en) * 2004-02-09 2013-02-19 Hill's Pet Nutrition, Inc. Composition and method for use in cartilage affecting conditions
US20050176674A1 (en) * 2004-02-09 2005-08-11 Friesen Kim G. Composition and method for use in cartilage affecting conditions
KR100601080B1 (ko) * 2004-08-26 2006-07-19 가톨릭대학교 산학협력단 (-)-에피갈로카테킨 갈레이트를 유효성분으로 하는류마티스성 관절염 치료제
NZ589276A (en) 2005-02-03 2012-06-29 Topotarget Uk Ltd Combination therapies using hdac inhibitors and erlotinib (tarceva)
BRPI0520227A2 (pt) * 2005-04-11 2009-04-22 Matthias Rath uso de uma composiÇço nutriente para o tratamento de sarcoma e cÂncer de pràstata
BRPI0520221A2 (pt) 2005-04-11 2009-04-22 Matthias Rath uso de uma composiÇço nutriente que compreende polifenàis de chÁ verde para tratamento de osteossarcoma
CN101189003B (zh) 2005-05-13 2012-02-08 托波塔吉特英国有限公司 Hdac抑制剂的药物制剂
US8138359B2 (en) * 2005-07-26 2012-03-20 Mitsui Norin Co., Ltd. Stabilized 3-hydroxyflavan compositions and methods therefor
WO2007033356A2 (fr) * 2005-09-14 2007-03-22 Mitsui Norin Co., Ltd Compositions et procedes de modification d'enzymes de detoxification par des catechines du the vert
JP5377968B2 (ja) * 2005-11-10 2013-12-25 トポターゲット ユーケー リミテッド 癌治療のために単独で用いるまたは化学療法薬と併用するヒストンデアセチラーゼ（ｈｄａｃ）阻害剤
US20070212426A1 (en) * 2006-03-10 2007-09-13 Matthias Rath Composition and method of retarding viral activity and reducing viral replication
WO2007147128A2 (fr) 2006-06-16 2007-12-21 Summa Health System Médicament anti-cancéreux non toxique combinant de l'ascorbate, du magnésium et une naphtoquinone
GB0615781D0 (en) * 2006-08-09 2006-09-20 Coressence Ltd Prebiotic composition
US20080114054A1 (en) * 2006-11-14 2008-05-15 Rath Microbes Compositions and methods for reducing antimicrobial resistance of microbes
RU2328282C1 (ru) * 2007-04-23 2008-07-10 Закрытое акционерное общество "МираксБиоФарма" Фармацевтическая композиция для профилактики образования метастазов и повышения чувствительности (сенсибилизации) опухолей к химиотерапевтическим препаратам
US8617544B2 (en) * 2007-05-01 2013-12-31 Richard L. Kozlenko Compositions and methods for controlling lipid metabolism
GB0710536D0 (en) 2007-06-01 2007-07-11 Veritron Ltd Plant extract and its therapeutic use
JP2010540426A (ja) * 2007-09-25 2010-12-24 トポターゲット ユーケー リミテッド 特定のヒドロキサム酸化合物の合成方法
GB0725077D0 (en) * 2007-12-21 2008-01-30 Univ Murcia Antifolate com[ounds for the treatment of melanoma
AU2009220942B2 (en) * 2008-03-07 2015-05-28 Onxeo Dk, Branch Of Onxeo S.A., France Methods of treatment employing prolonged continuous infusion of Belinostat
RU2395281C2 (ru) * 2008-09-04 2010-07-27 Всеволод Иванович Киселев Фармацевтическая композиция для лечения диспластических процессов шейки матки
ES2534245T3 (es) 2008-11-04 2015-04-20 Vymedic, Llc Formulaciones de suplemento antiviral
US8677463B2 (en) * 2008-12-05 2014-03-18 At&T Intellectual Property I, Lp System and method for managing multiple sub accounts within a subcriber main account in a data distribution system
JP2009143928A (ja) * 2008-12-26 2009-07-02 Kyushu Univ ガロイルカテキン類の抗酸化活性の促進方法
GB0900555D0 (en) * 2009-01-14 2009-02-11 Topotarget As New methods
US8440237B2 (en) * 2009-04-27 2013-05-14 Mary Kay Inc. Botanical anti-acne formulations
IT1397522B1 (it) * 2009-12-21 2013-01-16 Solartium Entpr Ltd Uso di una combinazione per il trattamento dell'osteoartrosi
GB201015784D0 (en) 2010-09-20 2010-10-27 Bionature E A Ltd Anti-cancer compounds
EP3566691B1 (fr) 2011-12-19 2024-04-17 Mary Kay Inc. Procédé cosmétique pour blanchir la peau et uniformiser le teint avec des haricot azuki
RU2522547C1 (ru) * 2012-11-12 2014-07-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации Фармакологическая геропротекторная композиция и способ ее получения
US20140154702A1 (en) * 2012-11-30 2014-06-05 Endocyte, Inc. Methods For Treating Cancer Using Combination Therapies
JP2016519092A (ja) * 2013-03-18 2016-06-30 デンタルメッド ファーム ホールディング リミテッド 組成物におけるｎ−アセチルシステイン誘導体とクランベリーポリフェノールとの組み合わせ、並びに歯周疾患及びインプラント周囲炎を予防及び処置するための方法
BE1023772B9 (fr) * 2013-05-17 2017-08-02 Valore Composition a base d'un complexe de (+)-catechine et d'acide amine pour le traitement et la prevention du cancer
IN2013MU01528A (fr) * 2013-07-26 2015-06-26 Tata Memorial Ct
GB2520794A (en) * 2013-07-26 2015-06-03 Tata Memorial Ct Plant poly-phenol and copper (II) mediated degradation of DNA and RNA
US9849077B2 (en) 2014-03-10 2017-12-26 Mary Kay Inc. Skin lightening compositions
BE1022579A9 (fr) * 2014-11-10 2016-10-06 Valore Composition antimétastatique comprenant au moins un composé de type flavanol
CN105061533B (zh) * 2015-09-18 2018-02-09 福州大学 六甲氧基二氢黄酮‑鼠李糖基‑鼠李糖苷及其应用
CN106138036A (zh) * 2016-04-29 2016-11-23 陈西敬 抗坏血酸棕榈酸酯在制备抗肿瘤药物中的应用
IL265786B (en) 2016-10-03 2022-09-01 Houn Simon Hsia Materials and methods for increasing radiotherapy against cancer
US10905725B2 (en) 2017-06-13 2021-02-02 Houn Simon Hsia Compositions and methods for enhancing cancer chemotherapy
US12029765B2 (en) 2017-06-13 2024-07-09 Houn Simon Hsia Compositions and methods for treating cancer
EP3638269B1 (fr) 2017-06-13 2025-12-17 Houn Simon Hsia Supplément nutritionnel pour augmenter la radiothérapie cancéreuse
CN111529709A (zh) * 2020-06-03 2020-08-14 北京易思腾翻译服务有限公司 一种可用于体重控制且可逆转动脉粥样硬化的组合物
WO2022124386A1 (fr) * 2020-12-07 2022-06-16 L' Oreal Composition comprenant de l'acide ascorbique et un acide aminé cyclique
IT202200010592A1 (it) * 2022-05-23 2023-11-23 Neilos S R L “Composizione nutraceutica o farmaceutica per l’infertilità maschile”

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4243363A1 (de) * 1992-12-21 1994-06-23 Ulrich Dr Med Kuebler Behandlungsverfahren für Hauttrockenheit
US5962517A (en) 1997-01-31 1999-10-05 Murad; Howard Pharmaceutical compositions and methods for treating acne
US5817695A (en) * 1997-12-24 1998-10-06 Pellico; Michael A. Nutritional product with high fat, low carbohydrate and amino acid imbalance
EP0938897A1 (fr) * 1997-12-26 1999-09-01 Japanese Foundation For Cancer Research Inhibiteur de la telomerase
AT407821B (de) * 1998-03-24 2001-06-25 Franz Dr Stueckler Mittel auf der basis von naturstoffen
US6410061B1 (en) * 1999-03-30 2002-06-25 Purdue Research Foundation Tea catechins as cancer specific proliferation inhibitors
CA2377414A1 (fr) 1999-06-15 2000-12-21 John D. Potter Compositions de nutriments destines a reduire le risque de maladie, traitement associe, et methode de selection des constituants
US6299925B1 (en) * 1999-06-29 2001-10-09 Xel Herbaceuticals, Inc. Effervescent green tea extract formulation
US6448030B1 (en) * 2000-02-18 2002-09-10 University Of Nevada-Las Vegas Method for predicting the efficacy of anti-cancer drugs
DE60028376T2 (de) * 2000-10-09 2007-06-06 Rath, Matthias, Dr. Therapeutische Kombination des Ascorbats mit Lysin und Arginin für Verhinderung und Behandlung des Krebses
WO2007076492A2 (fr) 2005-12-28 2007-07-05 Sandisk Corporation Procedes et systemes d'ecriture dans des memoires remanentes procurant une duree de service accrue

Also Published As

Publication number Publication date
HUP0500498A2 (hu) 2005-08-29
EE200400032A (et) 2004-04-15
DE60318387T2 (de) 2008-12-18
WO2003057201A3 (fr) 2004-03-11
UA80692C2 (en) 2007-10-25
LV13248B (en) 2005-06-20
RU2301666C2 (ru) 2007-06-27
ES2298519T3 (es) 2008-05-16
RU2004124384A (ru) 2005-04-20
EP1465614B1 (fr) 2008-01-02
JP2005519055A (ja) 2005-06-30
ATE382343T1 (de) 2008-01-15
ZA200405075B (en) 2006-07-26
CA2471932A1 (fr) 2003-07-17
WO2003057201A2 (fr) 2003-07-17
US20030170319A1 (en) 2003-09-11
NZ533737A (en) 2006-02-24
HK1086489A1 (zh) 2006-09-22
AU2003235762A1 (en) 2003-07-24
BR0302672A (pt) 2004-02-25
PL215159B1 (pl) 2013-10-31
KR20040073559A (ko) 2004-08-19
HRP20040704A2 (en) 2004-10-31
LT5240B (lt) 2005-07-25
CN1731989A (zh) 2006-02-08
MXPA04006717A (es) 2004-11-10
NO20033950D0 (no) 2003-09-05
HUP0500498A3 (en) 2013-01-28
EP1465614A2 (fr) 2004-10-13
US20060142212A1 (en) 2006-06-29
CN100377706C (zh) 2008-04-02
US7041699B2 (en) 2006-05-09
LT2004076A (en) 2005-02-25
PL371282A1 (en) 2005-06-13
AU2003235762B2 (en) 2008-10-02
IL162646A0 (en) 2005-11-20
YU75003A (sh) 2006-08-17
DE60318387D1 (de) 2008-02-14

Similar Documents

Publication Publication Date Title
NO20033950L (no) Farmasöytisk n¶ringspreparat omfattende polyfenoler og anvendelse i behandling av kreft
Park et al. Extract of Punica granatum inhibits skin photoaging induced by UVB irradiation
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
BRPI0409969A (pt) composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto
AP1666A (en) Quinolinone derivatives as tyrosine kinase inhibitors.
IL183953A (en) Method of reducing oxidant induced damage of a food product, a pharmaceutical or stored blood and novel compounds therefor
ATE370139T1 (de) Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
NO20030301L (no) Nye heteroarylderivater og anvendelse derav som farmasöytika
DE60140234D1 (de) Epigallocatechin-gallate zur hemmung von angiogenese
IL162384A0 (en) Composition inhibiting matrix-metallproteinases for the treatment of neoplastic diseases
TNSN08057A1 (en) Combinations comprising dmxaa for the treatment of cancer
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
WO2006021888A3 (fr) Inhibition de la dihydrofolate reductase par des composes d'epigallocatechine gallate
ATE460168T1 (de) Nicht-radioaktives strontiummittel zur behandlung von krebs
JOP20210222A1 (ar) علاج الأورام الليفية بواسطة فيتامين د وعامل مثل جالات يبيجالوكاتشين (egcg)
BR0014751A (pt) Composto, estereoisÈmero ou mistura de estereoisÈmeros, composição farmacêutica, método de tratamento de um paciente em necessidade de tratamento antimicrobiano, e, uso de um composto
WO2003080624A3 (fr) Nouveaux dithiolopyrrolones ayant une action therapeutique
BRPI0520221A2 (pt) uso de uma composiÇço nutriente que compreende polifenàis de chÁ verde para tratamento de osteossarcoma
AR011476A1 (es) Nitrometilcetonas, su procedimiento de preparacion, composiciones que las contienen y su utilizacion para preparar medicamentos.
BRPI0409768A (pt) composto, uso de composto, composição farmacêutica, método para tratar e/ou prevenir cáncer, e, processo para preparar o composto
WO2003095471A3 (fr) Produits pharmaceutiques pour traiter des dysfonctionnements aigus de la circulation de la veine porte et de la veine hepatique
ATE361086T1 (de) Pharmazeutische zusammensetzungen rutin und lespedeza capitata extrakt enthaltend zur behandlung von ödemen
MXPA05013760A (es) Composicion y procedimiento de tratamiento del platanero y del bananero.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application